KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM, L3
News, Material Contracts
First Oral Anabolic (Bone Building) Peptide Tablet for Postmenopausal Women with Osteoporosis – FDA Type A Endpoint Alignment in July 2025
Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis
Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones
Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism
Earnings Release
Announces Second Quarter 2025 Financial Results and Business Updates
Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis
FY 2025
Q3
Q2
Q1
FY 2024
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
PRER14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload